GSK
GSK plc Healthcare - Pharmaceuticals Investor Relations →
GSK plc (GSK) closed at $49.67 as of 2026-05-15, trading 35.3% above its 200-week moving average of $36.71. The stock is currently moving closer to the line, down from 36.3% last week. With a 14-week RSI of 30, GSK is in oversold territory.
Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.87 ratio) is neutral — neither side is clearly dominating.
Over the past 2359 weeks of data, GSK has crossed below its 200-week moving average 39 times. On average, these episodes lasted 14 weeks. Historically, investors who bought GSK at the start of these episodes saw an average one-year return of +12.2%.
With a market cap of $99.7 billion, GSK is a large-cap stock. The company generates a free cash flow yield of 3.0%. Return on equity stands at 40.9%, indicating strong profitability. The stock trades at 4.5x book value.
Over the past 33.4 years, a hypothetical investment of $100 in GSK would have grown to $1010, compared to $3058 for the S&P 500. GSK has returned 7.2% annualized vs 10.8% for the index, underperforming the broader market over this period.
Free cash flow has been declining at a -2.6% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: GSK vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After GSK Crosses Below the Line?
Across 39 historical episodes, buying GSK when it crossed below its 200-week moving average produced an average return of +10.6% after 12 months (median +8.0%), compared to +10.8% for the S&P 500 over the same periods. 74% of those episodes were profitable after one year. After 24 months, the average return was +20.6% vs +22.7% for the index.
Each line shows $100 invested at the moment GSK crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices GSK would reach each dislocation threshold.
Dislocation Price Levels
Prices where GSK's Bean Score would hit each σ threshold. Valid until next earnings report (last report: 2026-03-31).
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $48.52 | Unusually cheap — potential buy zone |
| Value | +1σ | $53.31 | Cheap vs. own history |
| Fair Value | +0σ | $59.14 | Historical mean behavior |
| Expensive | -1σ | $66.42 | Expensive vs. own history |
| Deep Expensive | -2σ | $75.73 | Unusually expensive — potential trim zone |
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Historical Touches
GSK has crossed below its 200-week MA 39 times with an average 1-year return of +12.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 1993 | May 1993 | 8 | 10.1% | +12.0% | +1037.5% |
| May 1993 | Sep 1993 | 14 | 22.6% | -8.0% | +1045.4% |
| Sep 1993 | Oct 1993 | 2 | 1.7% | -5.3% | +971.0% |
| Nov 1993 | Nov 1993 | 4 | 5.1% | +4.9% | +954.2% |
| Jan 1994 | Dec 1994 | 50 | 21.4% | +9.6% | +934.3% |
| Jan 1995 | Jan 1995 | 1 | 3.5% | +46.2% | +891.9% |
| Feb 1995 | Feb 1995 | 1 | 1.4% | +47.8% | +867.3% |
| Feb 2000 | Feb 2000 | 1 | 1.5% | +24.0% | +257.3% |
| Mar 2001 | Apr 2001 | 6 | 6.7% | -0.3% | +221.3% |
| Aug 2001 | Sep 2001 | 6 | 9.0% | -19.7% | +195.7% |
| Oct 2001 | Nov 2003 | 107 | 33.1% | -24.7% | +192.4% |
| Dec 2003 | Dec 2003 | 1 | 0.8% | +4.5% | +223.9% |
| Jan 2004 | Sep 2004 | 35 | 10.1% | +5.3% | +221.8% |
| Oct 2004 | Oct 2004 | 2 | 1.1% | +28.7% | +237.9% |
| Jan 2008 | Jul 2008 | 24 | 12.6% | -23.6% | +167.5% |
| Jul 2008 | Aug 2008 | 1 | 1.4% | -13.1% | +163.9% |
| Aug 2008 | Nov 2009 | 66 | 36.3% | -9.1% | +160.7% |
| Dec 2009 | Dec 2009 | 1 | 1.0% | -0.3% | +171.4% |
| Jan 2010 | Aug 2010 | 34 | 17.3% | -0.5% | +176.1% |
| Jan 2011 | Feb 2011 | 4 | 4.1% | +26.6% | +188.1% |
| Dec 2014 | Dec 2014 | 1 | 1.0% | -2.1% | +106.1% |
| Dec 2014 | Jan 2015 | 2 | 1.5% | +0.6% | +106.3% |
| Jun 2015 | Aug 2015 | 9 | 4.7% | +8.3% | +99.8% |
| Aug 2015 | Apr 2016 | 34 | 10.7% | +14.9% | +103.6% |
| Jun 2016 | Jun 2016 | 3 | 2.6% | +11.6% | +93.4% |
| Oct 2016 | Feb 2017 | 17 | 8.5% | +4.4% | +90.3% |
| Aug 2017 | Aug 2017 | 3 | 3.8% | +9.6% | +94.4% |
| Oct 2017 | Mar 2018 | 22 | 10.9% | +14.8% | +105.5% |
| Mar 2020 | Mar 2020 | 2 | 9.8% | +15.9% | +95.7% |
| Oct 2020 | Nov 2020 | 4 | 9.6% | +12.9% | +74.4% |
| Dec 2020 | Dec 2020 | 1 | 1.5% | +28.1% | +74.2% |
| Feb 2021 | Mar 2021 | 6 | 7.0% | +34.4% | +78.6% |
| Mar 2021 | Apr 2021 | 1 | 0.9% | +29.2% | +72.7% |
| Aug 2022 | Apr 2023 | 34 | 20.2% | +2.1% | +61.5% |
| Apr 2023 | May 2023 | 1 | 0.7% | +18.7% | +56.7% |
| May 2023 | Sep 2023 | 16 | 6.1% | +31.4% | +58.5% |
| Oct 2023 | Nov 2023 | 4 | 3.0% | +12.7% | +60.1% |
| Nov 2024 | Feb 2025 | 12 | 7.4% | +47.9% | +59.8% |
| Apr 2025 | Apr 2025 | 1 | 2.8% | +74.8% | +50.5% |
| Average | 14 | — | +12.2% | — |
Frequently Asked Questions
Is GSK below its 200-week moving average?
No. GSK plc (GSK) is currently 35.3% above its 200-week moving average of $36.71. It would need to fall to $36.71 to cross below the line.
What is GSK's 200-week moving average price?
GSK plc's 200-week moving average is $36.71 as of 2026-05-15. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when GSK drops below its 200-week moving average?
GSK has crossed below its 200-week moving average 39 times in our data. On average, buying at that moment produced a one-year return of +12.2%. These dips have historically been decent entry points. These episodes lasted 14 weeks on average.
Is GSK a good value right now?
Here's what our data says about GSK as of 2026-05-15: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 30 (oversold). Free cash flow yield is 3.0%. Return on equity is 40.9%. Price-to-book is 4.5x. This is not a buy or sell recommendation — always do your own research.
How does GSK compare to the S&P 500?
Over the past 33.4 years, $100 invested in GSK would have grown to $1010, compared to $3058 for the S&P 500. That's 7.2% annualized vs 10.8% for the index. GSK has underperformed the broader market over this period.
Does GSK pay a dividend?
Yes. GSK plc currently pays a dividend yield of 363.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-15